Compare BRO & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRO | DGX |
|---|---|---|
| Founded | 1939 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 23.1B |
| IPO Year | 1994 | 1996 |
| Metric | BRO | DGX |
|---|---|---|
| Price | $57.58 | $192.55 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $82.07 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 2.4M | 931.6K |
| Earning Date | 04-27-2026 | 04-21-2026 |
| Dividend Yield | 1.07% | ★ 1.82% |
| EPS Growth | N/A | ★ 13.78 |
| EPS | 1.06 | ★ 2.24 |
| Revenue | $5,902,000,000.00 | ★ $11,035,000,000.00 |
| Revenue This Year | $25.61 | $7.53 |
| Revenue Next Year | $6.85 | $3.77 |
| P/E Ratio | ★ $57.00 | $86.63 |
| Revenue Growth | ★ 22.83 | 11.78 |
| 52 Week Low | $58.65 | $164.65 |
| 52 Week High | $113.84 | $213.50 |
| Indicator | BRO | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 25.98 | 44.69 |
| Support Level | N/A | $189.86 |
| Resistance Level | $69.58 | $193.04 |
| Average True Range (ATR) | 1.77 | 5.35 |
| MACD | -0.89 | -0.43 |
| Stochastic Oscillator | 0.00 | 22.72 |
Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The company's business is divided into two reportable segments: (i) the Retail segment, and (ii) the Specialty Distribution segment. The Retail segment provides a broad range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers, as well as non-insurance warranty services and products through automobile and recreational vehicle dealer services businesses. The Specialty Distribution segment consists of wholesale brokerage and specialty businesses. Its geographic area is U.S, U.K and Others.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.